- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Sargramostim
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2003
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 276
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lymphoma, Neutropenia
- Interventions
- filgrastim, pegfilgrastim, cisplatin, cytarabine, etoposide, methylprednisolone
- Biological · Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Omaha, Nebraska • Cleveland, Ohio
- Conditions
- Hodgkin Disease
- Interventions
- Filgrastim SD/01, Adriamycin, Bleomycin, Vinblastine, DTIC
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma
- Interventions
- filgrastim, lomustine, procarbazine hydrochloride, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Leukemia, Myeloma, Myeloproliferative Diseases
- Interventions
- Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire
- Drug · Procedure · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Severe Combined Immunodeficiency
- Interventions
- Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 3 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Lymphoma, Non-Hodgkin, HIV Infections
- Interventions
- Filgrastim, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Cytarabine, Dexamethasone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 7
- States / cities
- San Francisco, California • Denver, Colorado • Boston, Massachusetts + 3 more
- Conditions
- Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
- Interventions
- Docetaxel, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim
- Drug · Biological
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Neuroblastoma
- Interventions
- Topotecan, Cyclophosphamide, Cisplatin, Etoposide, Vincristine, Doxorubicin, Sargramostim
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- San Diego, California • Houston, Texas
- Conditions
- HIV Infections, Cytopenias
- Interventions
- Sargramostim
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- filgrastim, carboplatin, cyclophosphamide, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 14
- States / cities
- La Jolla, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Mitoxantrone, GM-CSF
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Neuroblastoma
- Interventions
- Hu3F8 With GM-CSF
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hematologic Diseases, Hematologic Malignancies
- Interventions
- Granulocyte Colony Stimulating Factor
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Hematological Malignancy, Neutropenia
- Interventions
- Not listed
- Lead sponsor
- Aaron Cumpston, PharmD, BCOP
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Ovarian Neoplasms
- Interventions
- taxol
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer, Lymphoma, Pain
- Interventions
- Pregabalin, Placebo
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- filgrastim, carboplatin, docetaxel, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Prostatic Neoplasms
- Interventions
- GM-CSF, thalidomide, docetaxel
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myocardial Infarction
- Interventions
- Filgrastim
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2007
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Leukemia, Lymphoma
- Interventions
- Rituximab, Fludarabine, Cyclophosphamide, Total Body Radiation, Fucosylated Regulatory T Cells, Cord Blood Infusions, Mycophenolate mofetil, Sirolimus, Bone Marrow Aspiration, G-CSF, Non-Fucosylated Regulatory T Cells
- Drug · Radiation · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Interferon alfa-2b, Zidovudine, Sargramostim
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1992
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Melanoma
- Interventions
- melanoma GVAX, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Neuroblastoma
- Interventions
- ch14.18 -NCI, ch14.18-UTC, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Aldesleukin (IL-2), Isotretinoin
- Biological · Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- Up to 8 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 10 more